Hepion Pharmaceuticals, Inc. stock is up 10.56% since 30 days ago. The next earnings date is Apr 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 9 December’s closed higher than November. 0% of analysts rate it a buy.
Hepion Pharmaceuticals, Inc. focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease.